Ron Levin
Managing Partner, AV Seed Fund and Doctors Innovate Fund @ Alumni Ventures
Ron Levin is a seed investor at Alumni Ventures focused on Software and Artificial Intelligence. Ron has spent his career in a variety of entrepreneurial, leadership and business development roles. He has been an angel investor and advisor to over a dozen technology startups. Ron was co-founder and CEO of Barcelona-based TravelPerk, a venture capital-backed travel management platform that is ranked as one of the world’s fastest-growing SaaScompanies as well as one of the most popular business travel booking tools in the market. Prior to TravelPerk, Ron started the B2B division of Booking.com and before that was a consultant with McKinsey & Co. Ron began his career at Lycos, one of the web’s pioneer search engine and web portals. He has lived in four European cities and traveled for business and pleasure to over 130 countries on six continents. Ron graduated from Babson College and received his MBA from Harvard Business School.
- Total investments:
- 179
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Ron Levin invests in
Stages Ron Levin invests in
Countries Ron Levin invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.5M–$8M
- Pre-Seed
- $500k–$4M
- Series A
- $8M–$24M
Investment Focus
Industry
- Software 44 (25%)
- Artificial Intelligence 43 (24%)
- Health Care 22 (12%)
- Information Technology 22 (12%)
- FinTech 14 (8%)
Stage
- Seed 117 (65%)
- Pre-Seed 31 (17%)
- Series A 11 (6%)
- Venture - Series Unknown 4 (2%)
- Funding Round 2 (1%)
Country
- United States 114 (64%)
- United Kingdom 7 (4%)
- Israel 6 (3%)
- Canada 4 (2%)
- Germany 3 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rime
|
Rime develops speech technologies for a wide range of customers. The company works on speech generation with a deep understanding of linguistic and sociolinguistic phenomena needed to create the next generation of text-to-speech tooling. | $24M / Series A / Jul 15, 2026 | |
Century Health
|
Century Health accelerates drug development and commercialization by applying AI to real-world data. It is far too slow today to answer critical questions because the richest clinical data is locked away in silos. Our platform does the heavy lifting to rapidly get you the insight you need, all while supporting the research community and protectingpatient privacy. | $5M / Seed / May 19, 2026 | |
Huskeys
|
The New Brain for Web App Security. It's not a WAF; It's a whole new ecosystem. | $8M / Seed / Mar 30, 2026 | |
Lux Aeterna
|
Lux Aeterna is a space infrastructure company that focuses on orbital activities through reentry and reusability. | $10M / Seed / Mar 10, 2026 | |
Spintly
|
Spintly is a wireless cloud-based access control platform which enables users to access doors using their smartphones and eliminates more than 95% of access control cabling in buildings. Current Access control systems need extensive wiring and are bulky, occupying a ton of space in server rooms. Current access and identity management systems arenot smartphone friendly and getting data to the cloud from such systems is not trivial. Spintly cloud based smart access control system uses a wireless BLE-mesh network of access control readers to eliminate the back-end access control wiring in a building and empowers users by letting them use their smartphone as an access control device. Spintly access control system is connected to the cloud 24x7 through a wireless gateway and allows real-time monitoring of access data. Spintly offers access management solutions to Enterprises, Co-working spaces, Co-living spaces, Hospitality clients and residential communities. | $8M / Series A / Feb 26, 2026 | |
Burst
|
Burst provides financial services aimed at reducing systemic barriers to healthy household finances. The company focuses on addressing inequities in credit scoring and offers solutions to improve financial health for individuals and families. | $2.1M / Seed / Feb 25, 2026 | |
The Bland Company
|
The Bland Company is a biotechnology and food startup headquartered in London, focused on developing simple, transformative ingredients. The company operates within the biotechnology research industry and has a small team, with a company size estimated between 2–10 employees. Its official website, theblandcompany.co, indicates it is preparing tolaunch products or services, as the site currently features a "Coming Soon" message along with a newsletter subscription option. | $2.7M / Pre-Seed / Feb 10, 2026 | |
Powerline
|
GigElev develops an intelligence platform to help in transforming the electricity grid and mobility. Its platform is for future smart cities where e-mobility and electricity grid are intertwined to help clients convert every EV to an active contributor of stability and resiliency of the electricity grid.The company was founded in 2021 and isheadquartered in San Jose, California. | $7M / Seed / Feb 03, 2026 | |
Loop AI - Delivery Intelligence Platform
|
A co-pilot for modern food brands | $14M / Series A / Feb 02, 2026 | |
Salvo Health
|
Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $8.5M / Series A / Jan 22, 2026 | |
| See all 179 investments → | |||
Co-Investors
About Alumni Ventures
Alumni Ventures identifies and co-invests in deals alongside various established venture capital firms across multiple stages, from pre-seed to later-stage growth. Investors can participate through annual funds containing multiple companies or via a syndicate for individual deal-by-deal selections. The firm maintains several distinct investmentteams that evaluate opportunities across sectors such as artificial intelligence, healthcare, and strategic technology.
Alumni Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Aaron Sandford
Graphic Designer
|
|||
|
Alea Capello
'People and Culture, Associate
|
|||
|
Alexandra Critch
Product Manager Lead MarTec
|
|||
|
Alex Ovabor
VenturesCorps Analyst
|
|||
|
Allison Newman
Paralegal, Compliance Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Ron Levin invest in?
Ron Levin invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 179 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ron Levin's check size?
Ron Levin typically joins rounds of $1.5M–$8M at Seed, $500k–$4M at Pre-Seed and $8M–$24M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ron Levin participates in.
How do I contact Ron Levin?
Public channels for Ron Levin include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ron Levin last invest?
The most recent investment recorded for Ron Levin closed in Jul 2026. Shizune tracks 179 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
